Co-administration of ketoconazole and tacrolimus to kidney transplant recipients : cost minimization and potential metabolic benefits
Joint Authors
Abbas, Manal
al-Amin, Sarah
al-Majdhub, Abd al-Rahman A.
Dablouk, Najat
Mahmud, Fatimah
Source
Saudi Journal of Kidney Diseases and Transplantation
Issue
Vol. 25, Issue 4 (31 Aug. 2014), pp.814-818, 5 p.
Publisher
Saudi Center for Organ Transplantation
Publication Date
2014-08-31
Country of Publication
Saudi Arabia
No. of Pages
5
Main Subjects
Topics
Abstract EN
To evaluate the effects of the co-administration of tacrolimus and ketoconazole to a group of kidney transplant recipients, we studied 30 kidney transplant recipients with stable kidney function who were maintained on tacrolimus-based immunosuppression.
They were prescribed ketoconazole (100 mg / day) with a concomitant reduction in daily tacrolimus dose to maintain its level within the therapeutic range.
The study included 19 males and 11 females with a mean age of 36 ± 12 years.
All patients were at least three months post-transplant and had tacrolimus trough levels within the therapeutic range of 5-7 ng / mL.
Desired tacrolimus trough levels could be achieved in 29 / 30 patients after the addition of ketoconazole.
This resulted in a significant reduction of the median tacrolimus dose from 5 mg / day (range 3-20 mg / day) at baseline to 2 mg / day (range 1-4 mg / day) (P = 0.00).
The median reduction in the tacrolimus dose was 63 % (range 50-83 %).
The median monthly tacrolimus cost dropped from 375 US$ per patient (range 225-1440 US$) to 150 US$ per patient (range 120-300 US$).
There were no reported adverse drug effects during the study period.
After one year of follow-up, there was a small but significant improvement in the estimated glomerular filtration rate (72 ± 18 versus 78 ± 20 mL / min, P = 0.01) and a significant reduction in serum uric acid levels (7.7 ± 1.7 versus 5.9 ± 0.8 mg / dL, P = 0.003).
The co-administration of ketoconazole and tacrolimus to kidney transplant recipients is safe and significantly reduces the cost of immunosuppression.
In addition, this combination appears to have a beneficial effect on kidney function.
American Psychological Association (APA)
al-Amin, Sarah& al-Majdhub, Abd al-Rahman A.& Dablouk, Najat& Mahmud, Fatimah& Abbas, Manal. 2014. Co-administration of ketoconazole and tacrolimus to kidney transplant recipients : cost minimization and potential metabolic benefits. Saudi Journal of Kidney Diseases and Transplantation،Vol. 25, no. 4, pp.814-818.
https://search.emarefa.net/detail/BIM-383492
Modern Language Association (MLA)
al-Amin, Sarah…[et al.]. Co-administration of ketoconazole and tacrolimus to kidney transplant recipients : cost minimization and potential metabolic benefits. Saudi Journal of Kidney Diseases and Transplantation Vol. 25, no. 4 (2014), pp.814-818.
https://search.emarefa.net/detail/BIM-383492
American Medical Association (AMA)
al-Amin, Sarah& al-Majdhub, Abd al-Rahman A.& Dablouk, Najat& Mahmud, Fatimah& Abbas, Manal. Co-administration of ketoconazole and tacrolimus to kidney transplant recipients : cost minimization and potential metabolic benefits. Saudi Journal of Kidney Diseases and Transplantation. 2014. Vol. 25, no. 4, pp.814-818.
https://search.emarefa.net/detail/BIM-383492
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 818
Record ID
BIM-383492